Zyversa Therapeutics, Inc. (ZVSA) — DEF 14A Filings
All DEF 14A filings from Zyversa Therapeutics, Inc.. Browse 4 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (4)
-
ZyVersa Therapeutics Files Definitive Proxy Statement
— Apr 17, 2025 Risk: low
ZyVersa Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) on April 17, 2025. The filing concerns the company's proxy materials, indicating it is a -
ZyVersa Therapeutics Files Definitive Proxy Statement
— Jan 17, 2025 Risk: low
ZyVersa Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on January 17, 2025. The filing concerns the company's proxy materials, indicating it is -
ZyVersa Therapeutics Files Definitive Proxy Statement
— Sep 9, 2024 Risk: low
ZyVersa Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) on September 9, 2024. The filing concerns the company's proxy materials, indicating it i -
ZyVersa Therapeutics Seeks Shareholder Approval for Potential Reverse Stock Split
— Mar 19, 2024 Risk: medium
ZyVersa Therapeutics, Inc. (ZVSA) filed a Proxy Statement (DEF 14A) with the SEC on March 19, 2024. ZyVersa Therapeutics is seeking shareholder approval for a r
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX